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Background: Pertuzumab, a human epidermal growth factor receptor (HER) 2 dimerization inhibitor, has
demonstrated promising efficacy in combination with trastuzumab in patients with metastatic breast cancer. As HER
signaling pathways are not only involved in oncogenesis, but also in myocardial homeostasis, an analysis of cardiac
safety data was undertaken in a large group of patients treated with pertuzumab.
Patients and methods: A complete database of patients treated with full-dose pertuzumab was used to describe
the incidence of asymptomatic left ventricular systolic dysfunction (LVSD) and symptomatic heart failure (HF).
Results: Information for 598 unique patients was available for the current analysis. Of the patients treated with
pertuzumab alone (n = 331) or pertuzumab in combination with a non-anthracycline-containing cytotoxic (n = 175) or
trastuzumab (n = 93), 23 (6.9%), 6 (3.4%), and 6 (6.5%), respectively, developed asymptomatic LVSD and 1 (0.3%), 2
(1.1%), and 1 (1.1%), respectively, displayed symptomatic HF. None of the 15 patients receiving both pertuzumab and
erlotinib demonstrated LVSD.
Conclusions: Patients treated with pertuzumab experienced relatively low levels of asymptomatic LVSD or
symptomatic HF. There was no notable increase in cardiac side-effects when pertuzumab was given in combination
with other anticancer agents.
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introduction
Pertuzumab, the first in a new class of targeted anticancer
agents known as human epidermal growth factor receptor
(HER) 2 dimerization inhibitors, inhibits the ability of HER2 to
pair with other HER family members [1]. Dimerization is
essential for HER signaling and is required for cell growth and
survival in many tumor types (Figure 1A). In addition to
blocking cell signaling, pertuzumab is capable of inducing
antibody-dependent cell-mediated cytotoxicity [10].
Besides their essential role in cell growth and survival, HER2
and HER4 receptors are also important for homeostatic
mechanisms in the cardiac myocyte [11]. HER2 and HER4 are
crucial for mouse embryonic heart development [12, 13], and it
has been demonstrated in rodents that HER2 expression is
required for the development of ventricular muscles and valves,
while activation of HER2 promotes cardiomyocyte survival [5,
14]. Moreover, in adult rat myocardium, neuregulin signaling
through HER2:HER4 heterodimers mediates synthesis and
stabilization of myocardial structural proteins and attenuates
myocyte death [5]. Although mice with a cardiac-restricted
deletion of HER2 survive into adulthood and initially show no
phenotypic abnormalities, they develop progressive
cardiomyopathy with left ventricular dysfunction and dilation
and are more susceptible to cardiac stress [15]. HER signaling is
also thought to play an important role in the sympathovagal
control systems of the heart [16, 17]. Therefore, despite the
anticancer benefits offered by HER2-targeted agents, there is
justified concern regarding the potential for undesirable effects
on the heart.
An asymptomatic decline in left ventricular ejection fraction
(LVEF), known as left ventricular systolic dysfunction (LVSD),
is recognized as a potential side-effect of therapy with the
HER2-targeted monoclonal antibody trastuzumab [8, 18],
although symptomatic heart failure (HF) is relatively
uncommon [17]. In a meta-analysis of randomized trials
employing adjuvant trastuzumab in patients with HER2-
positive early breast cancer, the likelihood of cardiac toxicity
was 2.45-fold higher in patients receiving trastuzumab
compared with those not receiving trastuzumab [19]. Most
cases of LVSD are asymptomatic and normalize on withdrawal
of therapy [20]. Myocardial dysfunction with anti-HER2
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Figure 1. Human epidermal growth factor receptor (HER) 2 signaling pathways involved in tumorigenesis and cardiac survival. (A) In breast cancer cells, HER
dimer formation results in cross-phosphorylation of the dimer tyrosine kinase domain and leads to the initiation of mitogenic cell signaling pathways, including
activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt pathways [2]. While the HER2 to HER3 heterodimer is
considered themostpotentHERdimerwith respect to strengthof interaction, ligand-induced tyrosinephosphorylation, anddownstreamsignaling, other dimerpairs
do showweakmitogenic activity [3]. BlockingHER2 signaling with trastuzumab [4] orHER2 dimerization with pertuzumab [1] prevents activation of the signaling
pathways thatmediate cell proliferation and survival. (B) In cardiacmyocytes, activation of cardiac stress pathways results in release of neuregulin that stimulates the
formation ofHER2:HER4andHER4:HER4 dimers. These activate downstream signaling pathways, resulting in the promotion of cardiomyocyte growth and cardiac
repairmechanisms [5–7].However, under conditionsofHER2inhibition, the homeostatic cardioprotection affordedby theactivationof thesedownstreampathways
may be attenuated, resulting in vulnerability to cardiac stress. (C) Anthracycline exposure exerts direct cytotoxicity against cardiac myocytes, resulting in the
cardiotoxic effects of these agents. Activation of the stress pathway described in panel B may afford some protection from the cytotoxic effects of anthracycline
exposure. However, it is possible that HER2 inhibition in the presence of anthracycline stress may further attenuate the innate cardioprotective mechanisms by
preventing the inductionofHER2:HER4-mediated stimulationof cardiomyocyte growthand cardiac repairmechanisms, thus limiting thecapacity for cardiac repair.
Therefore, inhibition of HER2 dimerization in association with anthracycline therapy can exacerbate anthracycline-induced cardiac damage [8, 9].
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therapy is thought to result primarily from a loss of tertiary
organization of the contractile proteins [6], which explains the
high rate of reversibility [21]. Discontinuation of trastuzumab
and treatment of cardiac dysfunction with standard HF therapy
may allow subsequent rechallenge with trastuzumab in selected
patients [22], although not all patients recover completely, even
with appropriate HF management [23, 24]. Conversely,
exposure to anthracycline is associated with ultrastructural
changes and LVSD that may be more permanent if not detected
early and managed appropriately [25, 26]. It is likely that the
underlying mechanism of anthracycline-induced cardiotoxicity
is different from that resulting from anti-HER2 treatments [6];
however, the two types of cardiotoxicity are not completely
independent, and anti-HER2 treatment has the potential to
worsen anthracycline toxicity [6, 27]. This may be due to the
inhibition by trastuzumab of the HER2:HER4 dimer-activated
pathways that play a crucial role in cardiomyocyte growth and
repair mechanisms during times of stress (Figure 1B and C) [8,
9, 18]. Moreover, the incidence of cardiac dysfunction is higher
in patients who have had prior anthracycline treatment, a known
cause of myocyte death, compared with those who have been
previously treated with a taxane, suggesting that inhibition of
cardiac repair mechanisms is a clinically relevant determinant of
LVSD [28]. Nonetheless, in most cases, LVSD attributable to
trastuzumab is recoverable with early identification and careful
reassessment [22, 29, 30]. The cardiac safety of the oral small
molecule HER1/HER2 inhibitor lapatinib has also been
evaluated. In a pooled analysis of clinical trial data for 3689
healthy volunteers and patients with various cancers [31], the
rate of adverse cardiac events was low and, events were generally
reversible. A more recent study in patients with trastuzumab-
refractory metastatic breast cancer (MBC) demonstrated a low
level of symptomatic and asymptomatic cardiac events when
lapatinib was given in combination with trastuzumab [32].
Pertuzumab has demonstrated promising efficacy in
combination with trastuzumab in patients with MBC [33, 34]. In
this report, we provide an exploratory but comprehensive analysis
of the pertuzumab cardiac safety data currently available from the
phase II clinical trials that were designed to explore the efficacy of
pertuzumab as monotherapy and in combination with
trastuzumab and other anticancer agents. Cardiac end points were
included in these studies, facilitating an exploratory analysis of the
cardiac safety of pertuzumab. The current analysis was undertaken
to provide insight for clinicians and guidance for future studies.
materials and methods
The incidence of cardiac dysfunction is described from all completed and
ongoing Roche and Genentech phase II studies in which full-dose
pertuzumab was given as a single agent (Table 1). Data are also included
from any study in which pertuzumab was combined with cytotoxic anti-
epidermal growth factor receptor (EGFR) (erlotinib) or anti-HER2
(trastuzumab) therapies (Table 1), excluding ongoing studies where data
analyses are yet to take place. The phase II studies were primarily designed
to explore the efficacy of pertuzumab, but cardiac end points were included
to assess for cardiac safety.
Cardiac exclusion criteria were similar across all studies with respect to
baseline LVEF (<50%–55%) and maximum prior cumulative dose of
anthracyclines (doxorubicin >360 mg/m2, epirubicin >720 mg/m2,
mitoxantrone >120 mg/m2, and idarubicin >90 mg/m2) (Table 1). All
patients underwent routine cardiac monitoring by echocardiography or
multiple-gated acquisition scans in general every two to four cycles (Table 1).
As different definitions of LVSD and symptomatic HF were used across
the studies included in the current analysis, data were reassessed to
identify all patients in any study who met standardized criteria for LVSD,
regardless of their cardiac status according to the original trial criteria.
Asymptomatic LVSD was defined as a decrease from baseline in LVEF of
‡10 absolute percentage points to a value of <50% at any post-baseline
LVEF assessment. LVEF readings were conducted and assessed by the
participating study centers (local assessment) for all except one study
(BO17929). For this study, central evaluations of LVEF were also
conducted. HF was defined as symptomatic LVSD and was based on
a decrease from baseline in LVEF of ‡10 absolute percentage points to
a value of <50% at any post-baseline LVEF assessment accompanied by
a physician diagnosis of a cardiac event, including any symptom plausibly
associated with HF (including dyspnea, edema, and fatigue) and/or any
recording of HF by an investigator.
pertuzumab as a single agent
Pertuzumab was given as a single agent in phase II studies in ovarian
cancer, non-small-cell lung cancer (NSCLC), castration-resistant prostate
cancer (CRPC), and MBC in which HER2 was not overexpressed [35–39].
Single-agent pertuzumab was also given to the third cohort of patients with
HER2-positive MBC enrolling in the phase II BO17929 study, primarily
investigating the efficacy and safety of pertuzumab plus trastuzumab [40]
(Table 1). Patients included in these studies had experienced progression or
recurrent disease despite previous treatment. Patients in studies TOC2689g,
TOC2572g, TOC2682g, BO17004, and BO16934 had not received any prior
HER2-targeted therapy [35–39], whereas those in BO17929 had progressed
following trastuzumab-based chemotherapy [40, 45].
pertuzumab in combination with cytotoxic agents
Patients received pertuzumab in combination with non-anthracycline-
containing cytotoxic therapy in phase I/Ib studies for various solid tumors and
in phase II studies for ovarian cancer [41–44] (Table 1). Patients with advanced
solid tumors were treated with pertuzumab in combination with cytotoxic
agents following progression during or after standard therapy [41, 42], whereas
patientswith platinum-sensitive [44] or platinum-resistant [43] ovarian cancer
were treated with pertuzumab plus cytotoxic agents after first-line therapy.
pertuzumab in combination with the anti-HER2
trastuzumab
Two studies have been reported in which patients with MBC who
experienced disease progression during trastuzumab treatment received
pertuzumab and trastuzumab together [33, 45]. In these studies, the
majority of patients had also received prior anthracycline treatment. In one
of these studies (BO17929), patients were stratified into one of the three
treatment cohorts. Cohorts 1 and 2 received pertuzumab in combination
with trastuzumab following disease progression on trastuzumab plus
chemotherapy. A third patient cohort was included following a protocol
amendment [40]. These patients received pertuzumab as monotherapy
following disease progression on trastuzumab plus chemotherapy; if they
experienced disease progression during pertuzumab monotherapy, they
were switched to pertuzumab plus trastuzumab.
pertuzumab in combination with the anti-EGFR agent
erlotinib
The combination of pertuzumab and erlotinib—an inhibitor of EGFR
tyrosine kinase signaling—is being investigated in an ongoing study in
patients with locally advanced or metastatic NSCLC that has progressed
following chemotherapy [46] (Table 1).
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Table 1. Overview of studies included in the analysis
Study no. (indication) Combination
partner(s)
N Median age
(range), years
Cardiac exclusion criteria Key prior treatment
exclusions
Cardiac monitoring
(frequency and method)
Pertuzumab phase II single-agent studies
TOC2689g [35] (ovarian),
NCT00058552
None 123 57 (35–83) LVEF <50% HER-targeted agents;
doxorubicin >360 mg/m2
or equivalent
Before cycles 3, 5, 7, 9, 13,
and 17 ECHO
TOC2572g [36] (NSCLC),
NCT00063154
None 43 62 (39–77) History of significant cardiac
disease
HER-targeted agents Before cycles 3, 5, 9, 13, and
17 ECHO
TOC2682g [37] (CRPC),
NCT00058539
None 41 68 (45–81) LVEF <50% HER-targeted agents;
doxorubicin >360 mg/m2
or equivalent
Every four cycles, ECHO or
MUGA
BO17004 [38] (CRPC) None 68 72 (57–84) LVEF <50%, known cardiac
condition
HER-targeted agents;
doxorubicin >360 mg/m2
or equivalent
At end of cycles 2 and 4, and
every four cycles thereafter,
ECHO or MUGA
BO16934 [39]
(HER2-negative MBC)
None 78 55 (33–78) LVEF <50%, history of
documented cardiac
disease
HER-targeted agents;
doxorubicin >360 mg/m2
or equivalent
At cycles 2, 4, 8, 12, 16, and
final visit, ECHO or
MUGA
BO17929 cohort 3 [40]
(HER2-positive MBC)
None 29 55 (38–65) LVEF <55%, decline of LVEF
to <50% with prior
trastuzumab therapy,
history of any cardiac AE
related to trastuzumab
therapy, history of
congestive HF
Doxorubicin >360 mg/m2 or
equivalent
At the end of cycles 2, 4, 6, 8,
and final visit, ECHO or
MUGA
Pertuzumab in combination with cytotoxic agents
BO17003 [41]
(solid tumors)
Capecitabine 18 65 (39–72) LVEF <50% HER-targeted agents;
doxorubicin >360 mg/m2
or equivalent
Every two cycles, ECHO or
MUGA
BO17021 [42]
(solid tumors)
Docetaxel 17 59 (22–69) LVEF <50% Doxorubicin >360 mg/m2 or
equivalent
Every 6 weeks, ECHO or
MUGA
TOC3258g [43] (ovarian),
NCT00096993
Gemcitabine 65 58 (18–81) LVEF <50% HER-targeted agents;
doxorubicin >360 mg/m2
or equivalent
Every 6 weeks, ECHO or
MUGA
BO17931 [44] (ovarian) Carboplatin +
gemcitabine or
carboplatin +
paclitaxel
75 59 (26–76) LVEF <50%, history of
NYHA ‡II HF
Any targeted therapy;
doxorubicin >360 mg/m2
or equivalent
At cycles 2, 4, and 6, and
every four cycles thereafter,
ECHO or MUGA
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Table 1. (Continued)
Study no. (indication) Combination
partner(s)
N Median age
(range), years
Cardiac exclusion criteria Key prior treatment
exclusions
Cardiac monitoring
(frequency and method)
Pertuzumab in combination with the anti-HER2 agent trastuzumab
BO17929 cohorts 1 and 2
[45] (HER2-positive
MBC)
Trastuzumab 66 55 (25–85) LVEF < 55%, decline of LVEF
to <50% with prior
trastuzumab therapy,
history of any cardiac AE
related to trastuzumab
therapy, history of HF
Doxorubicin >360 mg/m2
or equivalent
At the end of cycles 1, 2, 4, 6,
8, and final visit, ECHO or
MUGA
BO17929 cohort 3 [40]
(HER2-positive MBC)a
Trastuzumab added
following
progression
on pertuzumab
monotherapy
16 55 (38–65) LVEF <55%, decline of LVEF
to <50% with prior
trastuzumab therapy,
history of any cardiac AE
related to trastuzumab
therapy, history of
congestive HF
Doxorubicin >360 mg/m2
or equivalent
At the end of cycles 2, 4, 6, 8,
and final visit, ECHO or
MUGA
TOC3487s [33], NCI-
sponsored study
(HER2-positive MBC)
Trastuzumab 11 53 (36–68) LVEF <55%, clinical signs or
symptoms of HF
Doxorubicin >360 mg/m2
and/or liposomal
doxorubicin
Every 3 weeks before
treatment by
electrocardiogram and
ECHO. Cardiac MRI was
carried out at baseline for
patients who enrolled later
in the trial and for those
who had a reduction in
LVEF by ECHO scan
Pertuzumab in combination with the anti-EGFR agent erlotinib
WO20024 [46] (NSCLC) Erlotinib 15 60 (43–78) LVEF <50% Agents targeting growth
factors or their receptors;
doxorubicin >360 mg/m2
or equivalent
Day 15 of cycles 2, 4, and 6,
and every four cycles
thereafter, ECHO or
MUGA
aThese 16 patients are the subset of the total of 29 patients enrolled to cohort 3 who went on to receive trastuzumab on progression during pertuzumab monotherapy. AE, adverse event; CRPC, castration-
resistant prostate cancer; ECHO, echocardiogram; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; HF, heart failure; LVEF, left ventricular ejection fraction; MBC,
metastatic breast cancer; MRI, magnetic resonance imaging; MUGA, multiple-gated acquisition scan; NCI, National Cancer Institute; NSCLC, non-small-cell lung cancer; NYHA, New York Heart
Association.
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results
Information for 598 unique patients treated with pertuzumab
alone or in combination was available for the current analysis
(Table 2). Of these, 331 received pertuzumab as a single agent,
175 were treated with pertuzumab in combination with non-
anthracycline-containing cytotoxic agents, 93 were treated with
pertuzumab in combination with the anti-HER2 monoclonal
antibody trastuzumab, and 15 were treated with pertuzumab in
combination with the anti-EGFR agent erlotinib. Of the 93
patients receiving pertuzumab in combination with
trastuzumab, 16 had already received pertuzumab as a single
agent. The majority of patients in each of the MBC trials
(>70%) had received prior anthracycline therapy (Table 2).
Exposure to pertuzumab in these clinical studies varied
considerably depending upon the indication. The shortest
exposures were in patients with prostate cancer (study
BO17004), in whom the median treatment duration was 3
cycles, with a range of 2–11 cycles. The longest pertuzumab
exposures were in patients with HER2-positive breast cancer
(study BO17929). In this study, median pertuzumab exposure
was 9 cycles, with a range of 1–26 cycles.
pertuzumab as a single agent
Data from 331 (231 non-breast cancer and 100 MBC) patients
with available cardiac data who received pertuzumab as a single
agent were included in the analysis. Studies in patients with
ovarian cancer [35], NSCLC, and CRPC [36–38] demonstrated
that pertuzumab was associated with a 5.6% (13/231) incidence
of asymptomatic LVSD, with no documented cases of
symptomatic HF. Similarly, among 100 patients with MBC and
available post-baseline data who received pertuzumab [39, 40],
asymptomatic LVSD occurred in 10.0% of patients (10/100)
(Table 2). A single case of symptomatic HF was documented
among patients treated with single-agent pertuzumab; this
patient with MBC was a former smoker with hypertension and
prior anthracycline therapy [39] (Table 3). Evidence of reduced
LVEF was initially recorded on study day 290 after 14 cycles of
pertuzumab (last dose given on day 275). The next cycle of
pertuzumab was delayed by 4 weeks and was given on study day
323. An event of congestive HF was recorded on day 344 and,
the patient was withdrawn from the study.
pertuzumab in combination with cytotoxic agents
Of the 175 patients treated with pertuzumab in combination with
non-anthracycline-containing cytotoxic agents who had available
cardiac data, a total of six patients (3.4%) developed
asymptomatic LVSD. Two of these patients were being treated
with pertuzumab plus docetaxel (Taxotere, sanofi-aventis,
Bridgewater, NJ) for advanced solid tumors [42] and four with
pertuzumab plus gemcitabine- or carboplatin-based
chemotherapy for ovarian cancer [43, 44] (Table 2). In addition,
two patients, both with ovarian cancer, developed symptomatic
HF [43, 44]. One of these patients had no documented cardiac
risk factors, whereas the other was a smoker with hypertension
and hyperlipidemia (Table 3). The first of these two patients, a 41-
year-old woman, was treated with pertuzumab in combination
with paclitaxel (Taxol, Bristol-Myers Squibb Company, Princeton,
NJ) and carboplatin. HF was recorded at cycle 2 and treatment
was discontinued. The second patient, a 59-year-old female
smoker with chronic obstructive pulmonary disease, hypertension,
and hyperlipidemia received pertuzumab in combination with
gemcitabine. A gradual decline in LVEF was noted between cycles
6 and 14 and therapy was withdrawn at cycle 15 due to HF.
pertuzumab in combination with the anti-HER2
agent trastuzumab
In total, 93 patients who received pertuzumab in combination
with trastuzumab were analyzed for cardiac events.
Asymptomatic LVSD was observed in six patients (6.5%), all of
whom had MBC that had progressed following trastuzumab
therapy [33, 45] (Table 2). In addition, one patient with MBC
that had progressed after trastuzumab experienced
symptomatic HF at cycle 2. This patient had extensive left chest
wall disease and had been treated with left chest wall irradiation
and prior anthracyclines (Table 3) [33].
Patients with refractory HER2-positive MBC that had relapsed
on prior trastuzumab-containing therapy were examined in study
BO17929 [45]. In this study, patients were selected for adequate
cardiac function at baseline and treatment was associated with
a low incidence of clinical cardiac events. Three of 66 patients
(4.5%) in cohorts 1 and 2 experienced asymptomatic LVSD. No
patient experienced systolic HF (Table 2), and in two patients, the
asymptomatic LVSD resolved while continuing trastuzumab plus
pertuzumab therapy [45]. One of 16 patients (6.3%) in cohort 3
who received pertuzumab and trastuzumab following progressive
disease on pertuzumab monotherapy experienced asymptomatic
LVSD (Table 2). Data from a smaller National Cancer Institute-
sponsored study (TOC3487s) [33] demonstrated a higher
incidence of left ventricular dysfunction, with 2 of 11 patients
(18.2%) experiencing asymptomatic LVSD and 1 patient (9.1%)
developing symptomatic HF (Table 2). However, in this trial,
patients were not excluded if they had experienced previous
trastuzumab-associated cardiac dysfunction, and cardiac
monitoring was carried out more frequently than in study
BO17929 (every 3 weeks versus every 6 weeks) (Table 1).
pertuzumab in combination with the anti-EGFR
agent erlotinib
None of the 15 patients treated with a combination of
pertuzumab and erlotinib who were assessable for cardiac
toxicity demonstrated LVSD or HF (Table 2) [46].
timing of LVSD and HF events in relation to
pertuzumab dosing
The median timing of LVSD and HF events was around cycle 4
(range 1–15 cycles) with 34/39 events (87%) occurring between
cycles 1 and 7.
discussion
The results of this analysis demonstrate that pertuzumab
(exposure ranging from a median of 3 cycles [range 2–11] to
a median of 26 cycles [range 1–26]) was generally well tolerated.
The incidence of LVSD was low, with most events being
asymptomatic and detected at scheduled evaluations. The
median timing of LVSD and HF was around cycle 4 (range 1–15)
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with 34/39 (87%) events occurring between cycles 1 and 7.
Additionally, when pertuzumab was given in combination with
trastuzumab or non-anthracycline-containing cytotoxic
chemotherapy, there was no marked increase in observed cardiac
dysfunction. In this analysis of 598 unique patients exposed to
pertuzumab, 35 (5.9%) cases of asymptomatic LVSD and 4
(0.7%) cases of symptomatic HF were reported. There have been
several recent publications examining HF rates among breast
cancer patients receiving trastuzumab as adjuvant therapy as well
as in patients with more advanced MBC [24, 30, 47]. In two
studies, patients received trastuzumab in the adjuvant setting
[30, 47]. In the first of these, Perez et al. [30] recorded an HF rate
of 2.8% for patients with primary, operable HER2-positive breast
cancer treated with paclitaxel followed by trastuzumab, and 3.3%
for those treated with paclitaxel plus trastuzumab followed by
trastuzumab alone. More recently, Russell et al. [47] reported
a symptomaticHF rate of 2.0% for 133 patients receiving adjuvant
trastuzumab therapy. In a study designed to evaluate the role of
troponin I in predicting cardiac damage, Cardinale et al. [24]
reported that among 251 women receiving treatment for early and
advanced breast cancer with trastuzumab, 42 (16.7%) experienced
trastuzumab-induced cardiotoxicity. In all three studies, whether
patients were receiving adjuvant treatment or therapy for
metastatic cancer, patients were selected on the basis of good
Table 2. Incidence of asymptomatic left ventricular systolic dysfunction and symptomatic heart failure, by study
Study no. (indication) Combination
partner(s)
No.
assessable
for cardiac
toxicity
Asymptomatic
LVSD, n (%)
Symptomatic
heart failure,
n (%)
Pertuzumab phase II single-agent studies
TOC2689g [35] (ovarian) None 99 3 (3.0) 0
TOC2572g [36] (NSCLC) None 30 1 (3.3) 0
TOC2682g [37] (HRPC) None 38 3 (7.9) 0
BO17004 [38] (HRPC) None 64 6 (9.4) 0
BO16934 [39] (MBC; 100% prior A) None 71 8 (11.3) 1 (1.4)
BO17929 cohort 3 [40] (MBC progressing on
trastuzumab; 72% prior A)
None 29 2 (6.9)a 0
Total single-agent 331 23 (6.9) [95% CI 4.5–10.2] 1 (0.3)
Pertuzumab in combination with cytotoxic agents
BO17003 [41] (solid tumors) Capecitabine 18 0 0
BO17021 [42] (solid tumors) Docetaxel 17 2 (11.8) 0
TOC3258g [43] (ovarian) Gemcitabine 65 2 (3.1) 1 (1.5)
BO17931 [44] (ovarian) Carboplatin +
gemcitabine
or carboplatin
+ paclitaxel
75 2 (2.7) 1 (1.3)
Total in combination with cytotoxics 175 6 (3.4) [95% CI 1.3–7.3] 2 (1.1)
Pertuzumab in combination with the anti-HER2 agent trastuzumab
TOC3487s [33], NCI-sponsored study (MBC progressing
on trastuzumab; 82% prior A)
Trastuzumab 11 2 (18.2) 1 (9.1)
BO17929 cohorts 1 and 2 [45] (MBC progressing
on trastuzumab; 70% prior A)
Trastuzumab 66 3 (4.5)b 0
BO17929 cohort 3 [40] (MBC progressing on trastuzumab;
72% prior A)
Trastuzumab
(added
following
progression
on pertuzumab
monotherapy)
16 1 (6.3) 0
Total in combination with trastuzumab 93 6 (6.5) [95% CI 2.4–13.5] 1 (1.1) [95% CI 0–5.8]
Pertuzumab in combination with the anti-EGFR agent erlotinib
WO20024 [46] (NSCLC) Erlotinib 15 0 0
Total in combination with erlotinib 15 0 [95% CI 0–21.8] 0 [95% CI 0–21.8]
Total unique pertuzumab-treated patientsc 598 35 (5.9) [95% CI 4.1–8.0] 4 (0.7) [95% CI 0.2–1.7]
aOf these, one had an LVEF decrease according to local readings only and one according to central readings only.
bOf these, one had an LVEF decrease according to local readings only and two according to central readings only.
cSixteen patients received both pertuzumab monotherapy and pertuzumab in combination with trastuzumab. A, anthracycline; HER, human epidermal
growth factor receptor; HRPC, hormone-resistant prostate cancer; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; MBC,
metastatic breast cancer; NCI, National Cancer Institute; NSCLC, non-small-cell lung cancer.
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performance status, adequate cardiac function (as indicated by
baseline LVEF), and other indicators of physiological status,
including adequate liver andbonemarrow functionand absenceof
significant medical history. Patients on these studies were,
therefore, of broadly similar physiological status. Probably the
major difference between these populations of patients receiving
trastuzumab and, indeed, between these trastuzumab patients and
those described in the current analysis who were treated with
pertuzumab, however, is the difference in timing between the
anthracycline and anti-HER2 therapies they received. Those
patients receiving adjuvant therapy were more likely to have had
recent exposure to anthracycline, whereas in those being treated
forMBC, substantial periods of time (up to several years)mayhave
elapsed since anthracycline exposure, and this should be
considered when making comparisons between studies.
In one small study investigating pertuzumab plus trastuzumab
in MBC progressing after trastuzumab-containing therapy [33],
a higher rate of cardiac events was recorded than in any of the
other studies. The reasons for this are unclear but may be a result
of the lack of screening for adequate cardiac function during
prior treatment with trastuzumab, closer monitoring, using
a variety of monitoring methods, and amore stringent definition
of LVSD (a decrease in LVEF of £55% from baseline).
It is likely that the careful selection of patients lacking cardiac
comorbidities may contribute to the low rate of cardiac events
observed in studies where pertuzumab and trastuzumab are
combined. In study BO17929, patients were excluded if they
had experienced LVEF declines during previous trastuzumab
therapy [45], and in ongoing phase II and III breast cancer
studies [NEOSPHERE (NCT00545688) and CLEOPATRA
(NCT00567190), respectively], patients are excluded if they
have any relevant cardiac history (including HF), uncontrolled
hypertension, or poorly controlled diabetes mellitus.
Furthermore, in these studies, patients must have a limited
lifetime exposure to anthracyclines below 360 mg/m2 for
doxorubicin or liposomal doxorubicin or equivalent dosing for
epirubicin, mitoxantrone, and idarubicin. It is anticipated that
data from the CLEOPATRA study, which has a planned
enrollment of 800 patients, will provide further insights into the
safety profile of pertuzumab in combination with trastuzumab.
It should also be noted that the presence of HER2-positive
breast cancer tends to be skewed toward younger patients, who
are less likely to have cardiovascular problems [48].
It is possible that pertuzumab may appear to have a relatively
low cardiotoxic potential due to the timing of anthracycline
and pertuzumab treatment. In the adjuvant trastuzumab trials,
a shorter time between anthracycline and trastuzumab
treatment appeared to bear a higher risk of trastuzumab-
associated cardiotoxicity [8]. Due to the design of the studies in
this analysis, the time between anthracycline and pertuzumab
treatment was generally long—in most cases, several months or
years. In the adjuvant trastuzumab trials, most patients received
the first dose of trastuzumab between 3 and 12 weeks after the
end of anthracycline-based therapy [33, 40, 45].
implications for use of anti-HER2 therapies
The results of this analysis indicate that pertuzumab has the
potential to induce cardiac dysfunction and HF, although it is
currently difficult to assess whether the rate is similar to that ofT
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trastuzumab. The results also highlight that it is vital for
physicians to examine the full medical history of patients before
they receive anti-HER2 therapies, to identify potential risk
factors for cardiac dysfunction, and an LVEF assessment before
chemotherapy to identify patients at higher risk of anti-HER2
cardiotoxicity [49, 50]. Cardiac status should be optimized
before treatment with anti-HER2 therapies, and the potential
benefits of treatment should be balanced against any potential
cardiac risk [51]. Recent preliminary evidence suggests that the
preventative use of angiotensin-converting enzyme inhibitors
in high-risk patients receiving high-dose chemotherapy
(identified by elevations in troponin I cardiac markers) may
prevent cardiac dysfunction with anti-HER2 therapy [51].
In the current analysis, most patients with breast cancer had
received prior anthracycline therapy, but the majority of this
exposure occurred early in the course of the disease (as either
neoadjuvant or adjuvant therapy), and no patient had been
exposed to anthracyclines beyond the established limits of
lifetime exposure. A study [TRYPHAENA (NCT00976989)] is
ongoing to evaluate the safety and efficacy of combined
treatment of HER2-positive breast cancer with trastuzumab,
pertuzumab, and epirubicin in the neoadjuvant setting.
In summary, as a single agent or in combination with
cytotoxic agents, including trastuzumab, pertuzumab has been
generally well tolerated by patients enrolled in the ongoing
clinical trial program, with a low incidence of cardiac
dysfunction, apparently similar to that associated with
trastuzumab. Nonetheless, it is important that cardiac risk
factors are taken into account when making a decision
regarding treatment with pertuzumab.
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